slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 24,871-24,900
Pages 1,437
Rows per page 30
Arc
24,871-24,900 of 43,093
14
The chart on the right uses a log scale for the y-axis to visualize selectivity indices.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
15
The slide uses a side-by-side comparison framework to delineate the two phases of the clinical trial.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
16
The slide details the patient population (N=35) and the subset of response-evaluable patients (N=21) across five dose cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
17
The data highlights a heavily pretreated population, with 77% having received 3 or more prior lines of therapy.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
18
Data as of 13 Sep 22. N=35 patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
19
The chart displays dose-dependent exposure over 24 hours, with horizontal dashed lines representing efficacy targets for different ROS1 variants in CNS and periphery.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
20
Clinical trial data table showing efficacy metrics for NVL-520.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
21
Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
Includes patient case study with longitudinal MRI scans.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Slide 26 of a pitch deck.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
Includes clinical trial data cut-offs and patient enrollment numbers.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide details specific patient cohorts (2a-2e) with varying treatment histories and trial objectives.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a list of icons to define the TPP.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
30
The table highlights the clinical challenge of resistance mutations and CNS involvement across different treatment lines.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
The slide uses a split-panel layout to contrast in vitro IC50 data with in vivo tumor regression data.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
The slide uses a bar chart for brain penetrance and a scatter plot for selectivity index to demonstrate the drug's therapeutic profile.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
The slide outlines the study design for NVL-655, detailing patient population, objectives, and cohort stratification.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
38
The chart demonstrates dose-proportional exposure and confirms that doses >= 50 mg QD exceed efficacy thresholds for various ALK mutations in the CNS.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
39
The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
40
The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
41
Clinical trial data visualization showing ORR and best percentage change in target lesions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
42
The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
43
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit